Cannabis Users on Buprenorphine Had 2.7x Higher Drug Levels — a Clinically Significant Interaction

Among opioid maintenance therapy patients on buprenorphine, those who also used cannabis had dramatically different pharmacokinetics. Cannabis users had 2.7-fold higher buprenorphine blood concentrations (p < 0.01) and 1.4-fold higher norbuprenorphine (the active metabolite) compared to non-users receiving the same dose.

The metabolite-to-parent drug ratio told the clearest story: 0.98 in non-users versus 0.38 in cannabis users (p = 0.02). Cannabis was blocking the CYP3A4 enzyme that converts buprenorphine to norbuprenorphine, causing the parent drug to accumulate in the blood. This wasn't a subtle effect — it was a nearly 3-fold difference in drug exposure at identical doses.

Sex did not significantly modify the interaction. The clinical implication was direct: opioid maintenance patients who use cannabis are effectively getting a higher dose than prescribed, with potential consequences for both efficacy and side effects.

Cannabis use among opioid maintenance patients is extremely common — by some estimates, the majority use cannabis at least occasionally. This study showed that combination isn't pharmacologically neutral: cannabis nearly triples buprenorphine blood levels. For a medication with a ceiling effect on respiratory depression (which is why buprenorphine is considered safer than methadone), this might matter less for overdose risk. But it could affect sedation, cognition, treatment compliance, and how doses are adjusted.

This is a concrete, clinically actionable drug interaction that most addiction medicine prescribers aren't accounting for.